Two medtech issuers report on October 27 with revenue growth expected

what happened

OrthoPediatrics is due to report quarterly results on October 27 for the period ended September 30, 2026. The mean estimate of eight analysts, based on LSEG data, puts revenue at $68.497 million, up 11.8% from $61.25 million a year earlier. The expected loss is 21 cents per share.

Pulmonx, based in Redwood City, California, also reports on October 27 for the same period. Five analysts expect revenue of $21.944 million, a 2.1% rise from $21.5 million a year ago. The expected loss is 26 cents per share.

The figures come from Earnings Preview, citing LSEG data. Ratings are mostly positive for both: OrthoPediatrics has 7 buy and 1 hold recommendations, while Pulmonx has 3 buy and 2 hold. The median 12-month price targets are $25.00 against a last close of $24.71 for OrthoPediatrics, and $3.00 against $1.88 for Pulmonx.

why it matters

Both companies are small medtech names, so the reports are unlikely to move the broader market. For investors in these stocks, revenue and loss trends matter most. According to LSEG, mean earnings estimates were unchanged over the past three months. In the previous quarter, OrthoPediatrics met its estimate, while Pulmonx beat expectations on its loss.

tags

instruments